The US Food and Drug Administration (FDA) has approved the drug Xolair from Novartis and Roche to reduce allergic reactions after contact with food.
As the pharmaceutical companies Roche and Novartis announced, Xolair has been approved for patients with IgE-mediated food allergy.
Patients taking Xolair for food allergies should continue to avoid any foods to which they are allergic, the companies added.
Xolair, a prescription biologic medicine given as an injection, should not be taken as an emergency treatment for allergic reactions.
The FDA approval is based on positive data from the Phase 3 OUtMATCH trial, in which Xolair was tested in patients ages 1 to 55 with an allergy to peanut and at least two other food allergens, including milk, egg, wheat, cashew, hazelnut and walnut, was examined.
By Sabela Ojea
FRANKFURT (Dow Jones)
Selected leveraged products on Novartis
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Novartis
The leverage must be between 2 and 20
Advertising